Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Shenzhen BioScien Acquires China Rights to Generex Cancer Vaccine

publication date: Dec 8, 2017

Shenzhen BioScien in-licensed greater China rights to an immunotherapeutic vaccine for prostate cancer from Generex Biotech of the US in a $5 million agreement. In a Phase I trial, conducted by Generex's subsidiary Antigen Express, AE37 produced an activation of T cells in patients with prostate cancer. Generex said the activation was robust, long-term, and specific. BioScien will develop the drug for mainland China plus Taiwan, Hong Kong and Macau. More details....

Stock Symbol: (OTCQB:GNBT)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.